HEPA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HEPA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), the Forward Annual Dividend Yield of Hepion Pharmaceuticals is 0.00%.
As of today (2024-06-10), the Trailing Annual Dividend Yield of Hepion Pharmaceuticals is 0.00%.
Hepion Pharmaceuticals's Dividends per Share for the three months ended in Mar. 2024 was $0.00.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
For the Biotechnology subindustry, Hepion Pharmaceuticals's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Hepion Pharmaceuticals's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Hepion Pharmaceuticals's Forward Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Hepion Pharmaceuticals (NAS:HEPA) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.
Thank you for viewing the detailed overview of Hepion Pharmaceuticals's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Wijngaard | director | 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Robert T Foster | officer: Chief Scientific Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Kaouthar Lbiati | director | 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Anand Reddi | director | 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
John T Cavan | officer: Chief Financial Officer | C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022 |
John P Brancaccio | director | C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852 |
Gary S Jacob | director, officer: CEO and President | |
Donald E Garlikov | 10 percent owner | 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215 |
Tamar D Howson | director | |
Thomas Phd Adams | director | |
Gabriel Cerrone | 10 percent owner | VIA SANT' ANDREA 18, MILAN L6 20121 |
John Z Sullivan-bolyai | officer: Chief Medical Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837 |
James Sapirstein | director, officer: Chief Executive Officer | 1517 SAN JACINTO, HOUSTON TX 77002 |
Arnold Lippa | director | C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016 |
William Karl Hornung | officer: Chief Financial Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170 |
From GuruFocus
By Marketwired • 09-14-2023
By Value_Insider Value_Insider • 12-05-2022
By Marketwired • 09-19-2023
By sperokesalga sperokesalga • 04-17-2023
By sperokesalga sperokesalga • 03-17-2023
By GuruFocus Research • 09-18-2023
By Value_Insider Value_Insider • 11-07-2022
By Value_Insider Value_Insider • 12-05-2022
By sperokesalga sperokesalga • 02-09-2023
By sperokesalga sperokesalga • 05-19-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.